Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation

[1]  P. Higgins,et al.  Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores: P-0057 , 2007 .

[2]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[3]  D. Symmons,et al.  Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. , 2006, Rheumatology.

[4]  S. Schreiber,et al.  Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[6]  S. Travis.  Advances in therapeutic approaches to ulcerative colitis and crohn’s disease , 2005, Current gastroenterology reports.

[7]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[8]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[9]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[10]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[11]  L. Aabakken,et al.  Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis , 2004, BMC gastroenterology.

[12]  F. Campbell,et al.  How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop , 2002, Journal of clinical pathology.

[13]  D. Levine,et al.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[14]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[15]  A. Munakata,et al.  Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. , 2000, Scandinavian journal of gastroenterology.

[16]  M. Seo,et al.  Correlation between endoscopic severity and the clinical activity index in ulcerative colitis , 1998, American Journal of Gastroenterology.

[17]  G. Svegliati-Baroni,et al.  Observer agreement in endoscopic assessment of ulcerative colitis. , 1998, Italian journal of gastroenterology and hepatology.

[18]  S. Hanauer,et al.  Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.

[19]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[20]  R. Modigliani,et al.  Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.

[21]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[22]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[23]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[24]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[25]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[26]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[27]  B. Scott,et al.  What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. , 1988, Journal of Clinical Pathology.

[28]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[29]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[30]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[31]  D. W. Day,et al.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis , 1982, Digestive Diseases and Sciences.

[32]  M. Dixon,et al.  An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis , 1973, Gut.

[33]  J. H. Baron,et al.  Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.

[34]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[35]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[36]  L. Witts,et al.  Cortisone in Ulcerative Colitis , 1954 .

[37]  J. Stockman.  Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin , 2007 .

[38]  S. Travis,et al.  Remission in Trials of Ulcerative Colitis: What Does It Mean? INFLAMMATORY BOWEL DISEASE: A PRACTICAL APPROACH, SERIES #26 , 2006 .

[39]  R. Riddell,et al.  Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. , 1999, Scandinavian journal of gastroenterology.

[40]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[41]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.